Abstract
Xifeng Jiannao Pill (XFJNP), a traditional Chinese medicine formulation, has been shown to alleviate clinical symptoms in patients with Parkinson’s disease (PD). However, the underlying mechanisms remain unclear. Therefore, this study employs network pharmacology and molecular biology to investigate the potential therapeutic mechanisms of XFJNP. Firstly, network pharmacology is utilized to screen the major active ingredients and potential targets of XFJNP in the treatment of PD. Following this, pathway enrichment analysis is conducted to gain insights into the underlying mechanisms. Secondly, an MPP+-induced SH-SY5Y cell model and an MPTP-induced PD mouse model to investigate the therapeutic effects and potential mechanisms of XFJNP on PD. By assessing apoptosis, oxidative stress (OS), inflammation, activation of the MAPK pathway, and conducting behavioral tests in mice, we aimed to elucidate the efficacy and underlying mechanisms of XFJNP in treating PD. Network pharmacology analysis indicates that the MAPK signaling pathway holds a key position in mediating the therapeutic effects of XFJNP for PD. In basic experimental studies, XFJNP significantly enhanced the survival rate of MPP+-induced SH-SY5Y cells in vitro, reduced OS and inflammation levels, and increased the expression of tyrosine hydroxylase (TH) protein. In the MPTP-induced PD mouse model, XFJNP effectively improved motor function and reduced the loss of dopaminergic (DA) neurons. Mechanistic studies suggest that XFJNP may mitigate OS and inflammatory responses in the substantia nigra by inhibiting the excessive activation of ERK, JNK, and p38 in the MAPK signaling pathway. Based on the results of network pharmacology analysis and experimental validation, XFJNP displays profound neuroprotective efficacy by modulating the MAPK signaling cascade, markedly diminishing neuroinflammation and mitigating OS-triggered apoptosis of DA neurons in PD models. Graphical Abstract
Funding Information
  • 2024 Medical Service and Security Capability Enhancement Subsidy Fund (Jin Cai She Zhi [2023] No. 164, Jin Cai She Zhi [2023] No. 164)
  • Tianjin Municipal Health Commission and Tianjin Municipal Administration of Traditional Chinese Medicine (Grant No. 2023120 and 2023122, Grant No. 2023120 and 2023122)
  • Tianjin Binhai New Area Health Research Project (Grant Nos. 2023BWKZ002 and 2022BWKQ016, Grant Nos. 2023BWKZ002 and 2022BWKQ016)
  • Science and Technology Project of Binhai New Area Traditional Chinese Medicine Hospital (Grant Nos: Bhzy202301 and Bhzy202304, Grant Nos: Bhzy202301 and Bhzy202304)
  • Key Specialty of Integrated Traditional Chinese and Western Medicine Internal Medicine in Tianjin
  • Tianjin Science and Technology Plan Project (Grant No. 22ZYQYSY00030)
  • Tianjin Municipal Health Technology Project (Grant No.TJWJ2022XK04)
  • Tianjin Key Medical Discipline (Specialty) Construction Project (Grant No.TJYXZDXK-062B)
  • The 7th National Academic Experience Inheritance Program of Famous Chinese Medicine Experts

This publication has 30 references indexed in Scilit: